Prescribing guidelines do not recommend the long-term use of benzodiazepines since their effectiveness with chronic use is out-weighed by risks including dependence, memory and cognitive impairment, hip fractures and traffic accidents. Despite these guidelines, historical data points to an increasing proportion of inappropriate, repeat prescribing of benzodiazepines in Ireland and elsewhere, with up to 33% of patients who use these drugs doing so long-term. The typical long-term benzodiazepine user is an older, socio-economically disadvantaged patient who has been prescribed these medicines by their general practitioner (GP) and dispensed them by their community pharmacist. Misuse of benzodiazepines in nursing homes and psychiatric institutions is also of concern, with one Irish study indicating that almost half of all admissions to a psychiatric hospital were prescribed these drugs, usually despite a lack of clear clinical need. Discontinuation of benzodiazepines has proven to be of benefit, as it is followed by improvements in cognitive and psychomotor function, particularly in elderly patients. It is obvious that an inter-professional effort, focusing on the primary care setting, is required to address benzodiazepine misuse and to ensure appropriate pharmaceutical care. Pharmacists must be an integral part of this inter-professional effort, not least because they are uniquely positioned as the health professional with most frequent patient contact. There is already some supporting evidence that pharmacists’ involvement in interventions to reduce benzodiazepine use can have positive effects on patient outcomes. Here, this evidence is reviewed and the potential for pharmacists to play an expanded role in ensuring the appropriate use of benzodiazepines is discussed.
References
[1]
Donoghue, J.; Lader, M. Usage of benzodiazepines: A review. Int. J. Psychiatr. Clin. Prac. 2010, 14, 78–87, doi:10.3109/13651500903447810.
[2]
Lader, M.; Tylee, A.; Donoghue, J. Withdrawing benzodiazepines in primary care. CNS Drugs 2009, 23, 19–34, doi:10.2165/0023210-200923010-00002.
[3]
Arbanas, G.; Arbanas, D.; Dujam, K. Adverse effects of benzodiazepines in psychiatric outpatients. Psychiatr. Danub. 2009, 21, 103–107.
[4]
Spanemberg, L.; Nogueira, E.L.; Belem da Silva, C.T.; Dargel, A.A.; Menezes, F.S.; Neto, A.C. High prevalence and prescription of benzodiazepines for elderly: Data from psychiatric consultation to patients from an emergency room of a general hospital. Gen. Hosp. Psychiatry 2011, 33, 45–50, doi:10.1016/j.genhosppsych.2010.12.004.
[5]
Curran, H.V. Tranquillising memories: A review of the effects of benzodiazepines on human memory. Biol. Psychol. 1986, 23, 179–213, doi:10.1016/0301-0511(86)90081-5.
[6]
Tannenbaum, C.; Paquette, A.; Hilmer, S.; Holroyd-Leduc, J.; Carnahan, R. A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine, gabaergic and opioid drugs. Drugs Aging 2012, 29, 639–658.
[7]
Swift, C. Postural instability as a measure of sedative drug response. Br. J. Clin. Pharmacol. 1984, 18, 87S, doi:10.1111/j.1365-2125.1984.tb02586.x.
[8]
Wu, C.S.; Wang, S.C.; Chang, I. The association between dementia and long-term use of benzodiazepine in the elderly: Nested case-control study using claims data. Am. J. Geriatr. Psychiatry 2009, 17, 614–620, doi:10.1097/JGP.0b013e3181a65210.
[9]
Nurmi-Luthje, I.; Kaukonen, J.P.; Luthje, P.; Naboulsi, H.; Tanninen, S.; Kataja, M.; Kallio, M.L.; Leppilampi, M. Use of benzodiazepines and benzodiazepine-related drugs among 223 patients with an acute hip fracture in Finland: Comparison of benzodiazepine findings in medical records and laboratory assays. Drugs Aging 2006, 23, 27–37, doi:10.2165/00002512-200623010-00003.
[10]
Leufkens, T.R.M.; Vermeeren, A. Highway driving in the elderly the morning after bedtime use of hypnotics: A comparison between temazepam 20 mg, zopiclone 7.5 mg, and placebo. J. Clin. Psychopharmacol. 2009, 29, 432–438, doi:10.1097/JCP.0b013e3181b57b43.
[11]
Woolcott, J.C.; Richardson, K.J.; Wiens, M.O.; Patel, B.; Marin, J.; Khan, K.M.; Marra, C.A. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch. Intern. Med. 2009, 169, 1952–1960, doi:10.1001/archinternmed.2009.357.
[12]
Zint, K.; Haefeli, W.E.; Glynn, R.J.; Mogun, H.; Avorn, J.; Sturmer, T. Impact of drug interactions, dosage, and duration of therapy on the risk of hip fracture associated with benzodiazepine use in older adults. Pharmacoepidemiol. Drug Saf. 2010, 19, 1248–1255, doi:10.1002/pds.2031.
[13]
Kirby, M.; Denihan, A.; Bruce, I.; Radic, A.; Coakley, D.; Lawlor, B.A. Benzodiazepine use among the elderly in the community. Int. J. Geriatr. Psychiatry 1999, 14, 280–284, doi:10.1002/(SICI)1099-1166(199904)14:4<280::AID-GPS898>3.0.CO;2-O.
[14]
Puustinen, J.; Nurminen, J.; Kukola, M.; Vahlberg, T.; Laine, K.; Kivela, S.L. Associations between use of benzodiazepines or related drugs and health, physical abilities and cognitive function: A non-randomised clinical study in the elderly. Drugs Aging 2007, 24, 1045–1059, doi:10.2165/00002512-200724120-00007.
[15]
Obiora, E.; Hubbard, R.; Sanders, R.D.; Myles, P.R. The impact of benzodiazepines on occurrence of pneumonia and mortality from pneumonia: A nested case-control and survival analysis in a population-based cohort. Thorax 2013, 68, 163–170, doi:10.1136/thoraxjnl-2012-202374.
[16]
El-Aneed, A.; Alaghehbandan, R.; Gladney, N.; Collins, K.; Macdonald, D.; Fischer, B. Prescription drug abuse and methods of diversion: The potential role of a pharmacy network. J. Subst. Use 2009, 14, 75–83, doi:10.1080/14659890802446087.
[17]
Charlson, F.; Degenhardt, L.; McLaren, J.; Hall, W.; Lynskey, M. A systematic review of research examining benzodiazepine related mortality. Pharmacoepidemiol. Drug Saf. 2009, 18, 93–103, doi:10.1002/pds.1694.
[18]
Mallon, L.; Broman, J.E.; Hetta, J. Is usage of hypnotics associated with mortality? Sleep Med. 2009, 10, 279–286, doi:10.1016/j.sleep.2008.12.004.
[19]
Bellerose, D.; Lyons, S.; Carew, A.; Walsh, S.; Long, J. Problem Benzodiazapine Use in Ireland: Treatment (2003 to 2008) and Deaths (1998 to 2007). Available online: http://www.hrb.ie/publications/hrb-publication/publications//532/ (accessed on 24 June 2013).
[20]
Krska, J.; MacLeod, T. Sleep quality and the use of benzodiazepine hypnotics in general practice. J. Clin. Pharm. Ther. 1995, 20, 91–96, doi:10.1111/j.1365-2710.1995.tb00634.x.
[21]
Martin, J.L.R.; Sainz-Pardo, M.; Furukawa, T.A.; Martin-Sanchez, E.; Seoane, T.; Galan, C. Review: Benzodiazepines in generalized anxiety disorder: Heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials. J. Psychopharmacol. 2007, 21, 774–782.
[22]
Glass, J.; Lanct？t, K.L.; Herrmann, N.; Sproule, B.A.; Busto, U.E. Sedative hypnotics in older people with insomnia: Meta-analysis of risks and benefits. BMJ 2005, 331, 1169, doi:10.1136/bmj.38623.768588.47.
[23]
Kasper, S.; Resinger, E. Panic disorder: The place of benzodiazepines and selective serotonin reuptake inhibitors. Eur. Neuropsychopharmacol. 2001, 11, 307–321, doi:10.1016/S0924-977X(01)00100-6.
[24]
Otto, M.W.; Pollack, M.H.; Gould, R.A.; WorthingtonIII, J.J.; McArdle, E.T.; Rosenbaum, J.F.; Heimberg, R.G. A comparison of the efficacy of clonazepam and cognitive-behavioral group therapy for the treatment of social phobia. J. Anxiety Disord. 2000, 14, 345–358, doi:10.1016/S0887-6185(00)00027-X.
[25]
Otto, M.W.; McHugh, R.K.; Simon, N.M.; Farach, F.J.; Worthington, J.J.; Pollack, M.H. Efficacy of CBT for benzodiazepine discontinuation in patients with panic disorder: Further evaluation. Behav. Res. Ther. 2010, 48, 720–727, doi:10.1016/j.brat.2010.04.002.
[26]
Zandstra, S.; van Rijswijk, E.; Rijnders, C.A.T.; van de Lisdonk, E.; Bor, J.; van Weel, C.; Zitman, F. Long-term benzodiazepine users in family practice: Differences from short-term users in mental health, coping behaviour and psychological characteristics. Fam. Pract. 2004, 21, 266–269, doi:10.1093/fampra/cmh309.
[27]
Rickels, K.; Case, W.G.; Schweizer, E.; Garcia-Espana, F.; Fridman, R. Long-term benzodiazepine users 3 years after participation in a discontinuation program. Am. J. Psychiatry 1991, 148, 757–761.
[28]
Salzman, C.; Fisher, J.; Nobel, K.; Glassman, R.; Wolfson, A.; Kelley, M. Cognitive improvementfollowing benzodiazepine discontinuation in elderly nursing home residents. Int. J. Geriatr. Psychiatry 1992, 7, 89–93, doi:10.1002/gps.930070205.
[29]
Curran, H.; Collins, R.; Fletcher, S.; Kee, S.; Woods, B.; Iliffe, S. Older adults and withdrawal from benzodiazepine hypnotics in general practice: Effects on cognitive function, sleep, mood and quality of life. Psychol. Med. 2003, 33, 1223–1237, doi:10.1017/S0033291703008213.
[30]
Cahir, C.; Fahey, T.; Teeling, M.; Teljeur, C.; Feely, J.; Bennett, K. Potentially inappropriate prescribing and cost outcomes for older people: A national population study. Br. J. Clin. Pharmacol. 2010, 69, 543–552, doi:10.1111/j.1365-2125.2010.03628.x.
[31]
Benzodiazepines: Good Practice Guidelines for Clinicians. Available online: http://www.dohc.ie/publications/benzodiazepines_good_practice_guidelines.html (accessed on 24 June 2013).
[32]
Committee on Safety of Medicines. Benzodiazepines, dependence and withdrawal symptoms. Curr. Probl. 1988, 21, 1–2.
[33]
Jorgensen, V.R. Benzodiazepine and cyclopyrrolone reduction in general practice—does this lead to concomitant change in the use of antipsychotics? A study based on a Danish population. J. Affect. Disord. 2010, 126, 293–298, doi:10.1016/j.jad.2010.03.008.
[34]
Salzman, C. The APA Task Force report on benzodiazepine dependence, toxicity, and abuse. Am. J. Psychiatry 1991, 148, 151.
[35]
Smith, A.J.; Tett, S.E. Interventions to improve benzodiazepine prescribing, lessons from the past 20 years to guide future interventions. BMC Health Serv. Res. 2010, doi:10.1186/1472-6963-10-321.
[36]
Royal Australian College of General Practioners. Benzodiazepine Guidelines. Available online: http://www.racgp.org.au/guidelines/benzodiazepines (accessed on 24 June 2013).
[37]
Straand, J.; Rokstad, K. General practitioners’ prescribing patterns of benzodiazepine hypnotics: Are elderly patients at particular risk for overprescribing? Scand. J. Prim. Health Care Suppl. 1997, 15, 16–21, doi:10.3109/02813439709043423.
[38]
Hartikainen, S.; Rahkonen, T.; Kautiainen, H.; Sulkava, R. Kuopio 75+ study: Does advanced age predict more common use of psychotropics among the elderly? Int. Clin. Psychopharmacol. 2003, 18, 163–167.
[39]
National Institute for Health and Clinical Excellence. Clinical Guideline 113: Management of anxiety (panic disorder, with or without agoraphobia, and generalised anxiety disorder) in adults in primary, secondary and community care. Available online: http://www.nice.org.uk/nicemedia/live/13314/52599/52599.pdf (accessed on 24 June 2013).
[40]
Ciuna, A.; Andretta, M.; Corbari, L.; Levi, D.; Mirandola, M.; Sorio, A.; Barbui, C. Are we going to increase the use of antidepressants up to that of benzodiazepines? Eur. J. Clin. Pharmacol. 2004, 60, 629–634, doi:10.1007/s00228-004-0810-8.
[41]
Veronese, A.; Garatti, M.; Cipriani, A.; Barbui, C. Benzodiazepine use in the real world of psychiatric practice: Low-dose, long-term drug taking and low rates of treatment discontinuation. Eur. J. Clin. Pharmacol. 2007, 63, 867–873, doi:10.1007/s00228-007-0341-1.
[42]
Magrini, N.; Vaccheri, A.; Parma, E.; DíAlessandro, R.; Bottoni, A.; Occhionero, M.; Montanaro, N. Use of benzodiazepines in the Italian general population: Prevalence, pattern of use and risk factors for use. Eur. J. Clin. Pharmacol. 1996, 50, 19–25, doi:10.1007/s002280050063.
[43]
Balestrieri, M.; Marcon, G.; Samani, F.; Marini, M.; Sessa, E.; Gelatti, U.; Donato, F. Mental disorders associated with benzodiazepine use among older primary care attenders. Soc. Psychiatry Psychiatr. Epidemiol. 2005, 40, 308–315, doi:10.1007/s00127-005-0899-9.
[44]
Lagnaoui, R.; Depont, F.; Fourrier, A.; Abouelfath, A.; Begaud, B.; Verdoux, H.; Moore, N. Patterns and correlates of benzodiazepine use in the French general population. Eur. J. Clin. Pharmacol. 2004, 60, 523–529, doi:10.1007/s00228-004-0808-2.
[45]
Lasserre, A.; Younes, N.; Blanchon, T.; Cantegreil-Kallen, I.; Passerieux, C.; Thomas, G.; Chan-Chee, C.; Hanslik, T. Psychotropic drug use among older people in general practice: Discrepancies between opinion and practice. Br. J. Gen. Pract. 2010, 60, e156–e162, doi:10.3399/bjgp10X483922.
[46]
Cunningham, C.M.; Hanley, G.E.; Morgan, S. Patterns in the use of benzodiazepines in British Columbia: Examining the impact of increasing research and guideline cautions against long-term use. Health Policy 2010, 97, 122–129, doi:10.1016/j.healthpol.2010.03.008.
[47]
Simon, G.E.; Ludman, E.J. Outcome of new benzodiazepine prescriptions to older adults in primary care. Gen. Hosp. Psychiatry 2006, 28, 374–378, doi:10.1016/j.genhosppsych.2006.05.008.
[48]
Vasile, R.G.; Bruce, S.E.; Goisman, R.M.; Pagano, M.; Keller, M.B. Results of a naturalistic longitudinal study of benzodiazepine and SSRI use in the treatment of generalized anxiety disorder and social phobia. Depress. Anxiety 2005, 22, 59–67, doi:10.1002/da.20089.
[49]
Uchida, H.; Suzuki, T.; Mamo, D.C.; Mulsant, B.H.; Kikuchi, T.; Takeuchi, H.; Tomita, M.; Watanabe, K.; Yagi, G. Benzodiazepine and antidepressant use in elderly patients with anxiety disorders: A survey of 796 outpatients in Japan. J. Anxiety Disord. 2009, 23, 477–481, doi:10.1016/j.janxdis.2008.10.003.
[50]
Alonso, J.; Angermeyer, M.; Bernert, S.; Bruffaerts, R.; Brugha, T.; Bryson, H.; Girolamo, G.; Graaf, R.; Demyttenaere, K.; Gasquet, I. Psychotropic drug utilization in europe: Results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr. Scand. 2004, 109, 55–64.
[51]
Ohayon, M.M.; Lader, M.H. Use of psychotropic medication in the general population of France, Germany, Italy, and the United Kingdom. J. Clin. Psychiatry 2002, 63, 817–825, doi:10.4088/JCP.v63n0912.
[52]
Smith, A.J.; Sketris, I.; Cooke, C.; Gardner, D.; Kisely, S.; Tett, S.E. A comparison of benzodiazepine and related drug use in Nova Scotia and Australia. Can. J. Psychiatry 2008, 53, 545–552.
[53]
O’Mhaolin, A.; Gallagher, D.; O’Connell, H.; Chin, A.; Bruce, I.; Hamilton, F.; Tehee, E.; Coen, R.; Coakley, D.; Walsh, B. Benzodiazepine use amongst community dwelling elderly: 10 years on. Int. J. Geriatr. Psychiatry 2010, 25, 650–651, doi:10.1002/gps.2362.
[54]
Hallahan, B.; Murray, I.; McDonald, C. Benzodiazepine and hypnotic prescribing in an acute adult psychiatric in-patient unit. Psychiatr. Bull. 2009, 33, 12, doi:10.1192/pb.bp.107.018382.
[55]
Zandstra, S.M.; Furer, J.W.; van de Lisdonk, E.H.; Bor, J.H.; Zitman, F.G.; van Weel, C. Differences in health status between long-term and short-term benzodiazepine users. Br. J. Gen. Pract. 2002, 52, 805–808.
[56]
Neutel, C.I. The epidemiology of long-term benzodiazepine use. Int Rev Psychiatry 2005, 17, 189–197, doi:10.1080/09540260500071863.
[57]
Mant, A.; Duncan-Jones, P.; Saltman, D.; Bridges-Webb, C.; Kehoe, L.; Lansbury, G.; Chancellor, A.H. Development of long term use of psychotropic drugs by general practice patients. BMJ 1988, 296, 251–254, doi:10.1136/bmj.296.6617.251.
[58]
Van Hulten, R.; Teeuw, K.B.; Bakker, A.; Leufkens, H.G. Initial 3-month usage characteristics predict long-term use of benzodiazepines: An 8-year follow-up. Eur. J. Clin. Pharmacol. 2003, 58, 689–694.
[59]
Arroll, B. GPs should prescribe more benzodiazepines for the elderly. J. Prim. Health Care 2009, 1, 57.
[60]
Parr, J.M.; Kavanagh, D.J.; Young, R.M.D.; McCafferty, K. Views of general practitioners and benzodiazepine users on benzodiazepines: A qualitative analysis. Soc. Sci. Med. 2006, 62, 1237–1249, doi:10.1016/j.socscimed.2005.07.016.
[61]
Dempsey, O.P.; Moore, H. Psychotropic prescribing for older people in residential care in the UK, are guidelines being followed? Primary Care Commun. 2005, 10, 13–18, doi:10.1185/135525705X40364.
[62]
Rogers, A.; Pilgrim, D.; Brennan, S.; Sulaiman, I.; Watson, G.; Chew-Graham, C. Prescribing benzodiazepines in general practice: A new view of an old problem. Health 2007, 11, 181–198.
[63]
Srisurapanont, M.; Garner, P.; Critchley, J.; Wongpakaran, N. Benzodiazepine prescribing behaviour and attitudes: A survey among general practitioners practicing in Northern Thailand. BMC Fam. Pract. 2005, doi:10.1186/1471-2296-6-27.
[64]
Anthierens, S.; Habraken, H.; Petrovic, M.; Christiaens, T. The lesser evil? Initiating a benzodiazepine prescription in General Practice. Scand. J. Prim. Health 2007, 25, 214–219, doi:10.1080/02813430701726335.
[65]
Siriwardena, A.N.; Qureshi, Z.; Gibson, S.; Collier, S.; Latham, M. GPs’ attitudes to benzodiazepine and ‘z-drug’ prescribing: A barrier to implementation of evidence and guidance on hypnotics. Br. J. Gen. Pract. 2006, 56, 964–967.
[66]
Boixet, M.; Batlle, E.; Bolibar, I. Benzodiazepines in primary health care: A survey of general practitioners prescribing patterns. Addiction 1996, 91, 549–556, doi:10.1111/j.1360-0443.1996.tb02312.x.
[67]
Ten Wolde, G.B.; Dijkstra, A.; van Empelen, P.; Knuistingh Neven, A.; Zitman, F. Psychological determinants of the intention to educate patients about benzodiazepines. Pharm. World Sci. 2008, 30, 336–342, doi:10.1007/s11096-007-9183-2.
[68]
O’Reilly, C.L.; Simon Bell, J.; Chen, T.F. Pharmacists’ beliefs about treatments and outcomes of mental disorders: A mental health literacy survey. Aust. NZ J. Psychiat. 2010, 44, 1089–1096, doi:10.3109/00048674.2010.512864.
[69]
Oxman, A.D.; Thomson, M.A.; Davis, D.A.; Haynes, R.B. No magic bullets: A systematic review of 102 trials of interventions to improve professional practice. CMAJ 1995, 153, 1423–1431.
[70]
Van Grootheest, A.; Edwards, I.R. Labelling and ‘Dear Doctor’ letters: Are they noncommittal? Drug Saf. 2002, 25, 1051–1055, doi:10.2165/00002018-200225150-00001.
[71]
Batty, G.; Oborne, C.A.; Swift, C.; Jackson, S.H.D. Development of an indicator to identify inappropriate use of benzodiazepines in elderly medical in-patients. Int. J. Geriatr. Psychiatry 2000, 15, 892–896, doi:10.1002/1099-1166(200010)15:10<892::AID-GPS213>3.0.CO;2-X.
[72]
Batty, G.M.; Hooper, R.; Oborne, C.A.; Jackson, S. Investigating intervention strategies to increase the appropriate use of benzodiazepines in elderly medical in-patients. Br. J. Clin. Govern. 2001, 6, 252–258, doi:10.1108/14664100110408608.
[73]
Wan Md Adnan, W.A.H.; Zaharan, N.L.; Bennett, K.; Wall, C.A. Trends in co prescribing of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in ireland. Br. J. Clin. Pharmacol. 2010, 458–466.
[74]
Olsson, J.; Bergman, A.; Carlsten, A.; Oke, T.; Bernsten, C.; Schmidt, I.K.; Fastbom, J. Quality of drug prescribing in elderly people in nursing homes and special care units for dementia: A cross-sectional computerized pharmacy register analysis. Clin. Drug Investig. 2010, 30, 289–300, doi:10.2165/11534320-000000000-00000.
[75]
Bateman, D.; Eccles, M.; Campbell, M.; Soutter, J.; Roberts, S.; Smith, J. Setting standards of prescribing performance in primary care: Use of a consensus group of general practitioners and application of standards to practices in the North of England. Br. J. Gen. Pract. 1996, 46, 20–25.
[76]
Lipton, H.L.; Byrns, P.J.; Soumerai, S.B.; Chrischilles, E.A. Pharmacists as agents of change for rational drug therapy. Int. J. Technol. Assess. Health Care 1995, 11, 485–508, doi:10.1017/S0266462300008692.
[77]
Winslade, N.; Taylor, L.; Shi, S.; Schuwirth, L.; van der Vleuten, C.; Tamblyn, R. Monitoring community pharmacist's quality of care: A feasibility study of using pharmacy claims data to assess performance. BMC Health Serv. Res. 2011, doi:10.1186/1472-6963-11-12.
[78]
Morgan, J.D.; Wright, D.J.; Chrystyn, H. Pharmacoeconomic evaluation of a patient education letter aimed at reducing long-term prescribing of benzodiazepines. Pharm. World Sci. 2002, 24, 231–235, doi:10.1023/A:1021587209529.
[79]
Baillargeon, L.; Landreville, P.; Verreault, R.; Beauchemin, J.P.; Gregoire, J.P.; Morin, C.M. Discontinuation of benzodiazepines among older insomniac adults treated with cognitive-behavioural therapy combined with gradual tapering: A randomized trial. CMAJ 2003, 169, 1015–1020.
[80]
Morin, C.M.; Bastien, C.; Guay, B.; Radouco-Thomas, M.; Leblanc, J.; Vallieres, A. Randomized clinical trial of supervised tapering and cognitive behavior therapy to facilitate benzodiazepine discontinuation in older adults with chronic insomnia. Am. J. Psychiatry 2004, 161, 332–342, doi:10.1176/appi.ajp.161.2.332.
[81]
Oude Voshaar, R.C.; Gorgels, W.J.; Mol, A.J.; van Balkom, A.J.; van de Lisdonk, E.H.; Breteler, M.H.; van den Hoogen, H.J.; Zitman, F.G. Tapering off long-term benzodiazepine use with or without group cognitive-behavioural therapy: Three-condition, randomised controlled trial. Br. J. Psychiatry 2003, 182, 498–504, doi:10.1192/bjp.182.6.498.
[82]
Gosselin, P.; Ladouceur, R.; Morin, C.M.; Dugas, M.J.; Baillargeon, L. Benzodiazepine discontinuation among adults with GAD: A randomized trial of cognitive-behavioral therapy. J. Consult. Clin. Psychol. 2006, 74, 908–919, doi:10.1037/0022-006X.74.5.908.
[83]
Parr, J.M.; Kavanagh, D.J.; Cahill, L.; Mitchell, G.; Young, R. Effectiveness of current treatment approaches for benzodiazepine discontinuation: A meta-analysis. Addiction 2009, 104, 13–24.
[84]
Kippist, C.; Wong, K.; Bartlett, D.; Saini, B. How do pharmacists respond to complaints of acute insomnia? A simulated patient study. Int. J. Clin. Pharm. 2011, 33, 237–245, doi:10.1007/s11096-011-9482-5.
[85]
Cormack, M.A.; Owens, R.G.; Dewey, M.E. The effect of minimal interventions by general practitioners on long-term benzodiazepine use. J. R. Coll. Gen. Pract. 1989, 39, 408–411.
[86]
Heather, N.; Bowie, A.; Ashton, H.; McAvoy, B.; Spencer, I.; Brodie, J.; Giddings, D. Randomised controlled trial of two brief interventions against long-term benzodiazepine use: Outcome of intervention. Addict. Res. Theory 2004, 12, 141–154, doi:10.1080/1606635310001634528.
[87]
Cormack, M.; Sweeney, K.; Hughes-Jones, H.; Foot, G. Evaluation of an easy, cost-effective strategy for cutting benzodiazepine use in general practice. Br. J. Gen. Pract. 1994, 44, 5.
[88]
Gorgels, W.J.; Oude Voshaar, R.C.; Mol, A.J.; van de Lisdonk, E.H.; van Balkom, A.J.; van den Hoogen, H.J.; Mulder, J.; Breteler, M.H.; Zitman, F.G. Discontinuation of long-term benzodiazepine use by sending a letter to users in family practice: A prospective controlled intervention study. Drug Alcohol Depend. 2005, 78, 49–56, doi:10.1016/j.drugalcdep.2004.09.001.
[89]
Towle, I.; Adams, J. A novel, pharmacist-led strategy to reduce the prescribing of benzodiazepines in paisley. Pharm. J. 2006, 276, 136–138.
[90]
Dollman, W.B.; Leblanc, V.; Stevens, L.; O’Connor, P.; Roughead, E.E.; Gilbert, A.L. Achieving a sustained reduction in benzodiazepine use through implementation of an area-wide multi-strategic approach. J. Clin. Pharm. Ther. 2005, 30, 425–432, doi:10.1111/j.1365-2710.2005.00674.x.
[91]
Van de Steeg-van Gompel, C.; Wensing, M.; de Smet, P. Implementation of a discontinuation letter to reduce long-term benzodiazepine use—a cluster randomized trial. Drug Alcohol Depend. 2009, 99, 105–114, doi:10.1016/j.drugalcdep.2008.07.009.
[92]
Martin, P.; Tamblyn, R.; Ahmed, S.; Tannenbaum, C. A drug education tool developed for older adults changes knowledge, beliefs and risk perceptions about inappropriate benzodiazepine prescriptions in the elderly. Patient Educ. Couns. 2013, 92, 81–87, doi:10.1016/j.pec.2013.02.016.
[93]
Thomson, O.; Oxman, A.; Davis, D.; Haynes, R.; Freemantle, N.; Harvey, E. Educational outreach visits: Effects on professional practice and health care outcomes. Cochrane Database Syst. Rev. 2000, 2, CD000409.
[94]
Westbury, J.; Jackson, S.; Gee, P.; Peterson, G. An effective approach to decrease antipsychotic and benzodiazepine use in nursing homes: The REDUSE project. Int. Psychogeriatr. 2010, 22, 26–36, doi:10.1017/S1041610209991128.
[95]
Roberts, M.S.; Stokes, J.A.; King, M.A.; Lynne, T.A.; Purdie, D.M.; Glasziou, P.P.; Wilson, D.A.J.; McCarthy, S.T.; Brooks, G.E.; de Looze, F.J. Outcomes of a randomized controlled trial of a clinical pharmacy intervention in 52 nursing homes. Br. J. Clin. Pharmacol. 2001, 51, 257–265.
[96]
Schmidt, I.K.; Claesson, C.B.; Westerholm, B.; Nilsson, L.G. Physician and staff assessments of drug interventions and outcomes in swedish nursing homes. Ann. Pharmacother. 1998, 32, 27–32, doi:10.1345/aph.17104.
[97]
Crotty, M.; Halbert, J.; Rowett, D.; Giles, L.; Birks, R.; Williams, H.; Whitehead, C. An outreach geriatric medication advisory service in residential aged care: A randomised controlled trial of case conferencing. Age Ageing 2004, 33, 612–617, doi:10.1093/ageing/afh213.
[98]
Opedal, K.; Schjott, J.; Eide, E. Use of hypnotics among patients in geriatric institutions. Int. J. Geriatr. Psychiatry 1998, 13, 846–851, doi:10.1002/(SICI)1099-1166(1998120)13:12<846::AID-GPS880>3.0.CO;2-T.
[99]
Eide, E.; Schjott, J. Assessing the effects of an intervention by a pharmacist on prescribing and administration of hypnotics in nursing homes. Pharm. World Sci. 2001, 23, 227–231, doi:10.1023/A:1015142211348.
[100]
Gallagher, R.M.; Gallagher, H.C. Improving the working relationship between doctors and pharmacists: Is inter-professional education the answer? Adv. Health Sci. Educ. 2012, 17, 247–257, doi:10.1007/s10459-010-9260-5.
[101]
Soo, T.M.; Kljakovic, M.; Bishop, L.; Baxfield, N.; Dwan, K.; Toyne, H.; Zwikael, M.; Strang, J.; Bech, A. The benzodiazepine voluntary undertaking. A data audit and retrospective evaluation in the act. Available online: http://directionsact.com/pdf/drug_news/BenzoVolUndertaking.pdf (accessed on 24 June 2013).
[102]
Midlov, P.; Bondesson, A.; Eriksson, T.; Nerbrand, C.; Hoglund, P. Effects of educational outreach visits on prescribing of benzodiazepines and antipsychotic drugs to elderly patients in primary health care in southern sweden. Fam. Pract. 2006, 23, 60–64, doi:10.1093/fampra/cml923.
[103]
Lerat, M.C.; Cabelguenne, D.; Lassia, J.; Meunier, F.; Zimmer, L. Impact of pharmacist and clinician dual intervention on prescribed benzodiazepines in prisoner patients: A retrospective study. Fundam. Clin. Pharmacol. 2010, 25, 762–767.
[104]
Henman, M.; Vivero, L.; Gustaffson, A.; Mulvenna, K. Benzodiazepine Usage in the North Eastern Health Board Region of the Republic of Ireland. Available online: http://www.drugsandalcohol.ie/12699/ (accessed on 24 June 2013).
[105]
Monane, M.; Matthias, D.M.; Nagle, B.A.; Kelly, M.A. Improving prescribing patterns for the elderly through an online drug utilization review intervention: A system linking the physician, pharmacist, and computer. JAMA 1998, 280, 1249–1252, doi:10.1001/jama.280.14.1249.
[106]
Smith, A.J.; Tett, S.E. An intervention to improve benzodiazepine use—a new approach. Fam. Pract. 2010, 27, 320–327, doi:10.1093/fampra/cmq007.
[107]
Government of Ireland. Misuse of Drugs Act. Available online: http://www.irishstatutebook.ie/1984/en/act/pub/0018/index.html (accessed on 24 June 2013).
[108]
Butler, S. The making of the methadone protocol: The Irish system? Drugs Educ. Prev. Pol. 2002, 9, 311–324, doi:10.1080/09687630210148465.
[109]
Roberts, K. Revised drug misuse guidelines pharmacists must get more involved. Pharm. J. 1999, 263, 203–205.
[110]
Chung, K. Benzodiazepine prescribing trend after its inclusion as a dangerous drug under the Hong Kong dangerous drugs ordinance. Hong Kong Med. J. 1997, 3, 16–20.
[111]
Briesacher, B.A.; Soumerai, S.B.; Field, T.S.; Fouayzi, H.; Gurwitz, J.H. Medicare Part D’s exclusion of benzodiazepines and fracture risk in nursing homes. Arch. Intern. Med. 2010, 170, 693–698, doi:10.1001/archinternmed.2010.57.
[112]
Weintraub, M.; Singh, S.; Byrne, L.; Maharaj, K.; Guttmacher, L. Consequences of the 1989 New York State triplicate benzodiazepine prescription regulations. JAMA 1991, 266, 2392–2397, doi:10.1001/jama.1991.03470170080028.
[113]
De Gier, N.; Gorgels, W.; Lucassen, P.; Oude Voshaar, R.; Mulder, J.; Zitman, F. Discontinuation of long-term benzodiazepine use: 10-year follow-up. Fam. Pract. 2011, 28, 253–259, doi:10.1093/fampra/cmq113.
[114]
Godfrey, C.; Heather, N.; Bowie, A.; Brodie, J.; Parrott, S.; Ashton, H.; McAvoy, B. Randomised controlled trial of two brief interventions against long-term benzodiazepine use: Cost-effectiveness. Addict. Res. Theory 2008, 16, 309–317, doi:10.1080/16066350801900297.
[115]
Busto, U.; Sellers, E.M.; Naranjo, C.A.; Cappell, H.; Sanchez-Craig, M.; Sykora, K. Withdrawal reaction after long-term therapeutic use of benzodiazepines. NEJM 1986, 315, 854–859, doi:10.1056/NEJM198610023151403.
[116]
Beier, M.T.; Martin, C.M.H. Gradual dose reduction and medication tapering: A clinical perspective. Consult. Pharm. 2007, 22, 628–644, doi:10.4140/TCP.n.2007.628.
[117]
Denis, C.; Fatsv？as, M.; Lavie, E.; Auriacombe, M. Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings. Cochrane Database Syst. Rev. 2006, 3, CD005194.
[118]
Murphy, S.M.; Tyrer, P. A double-blind comparison of the effects of gradual withdrawal of lorazepam, diazepam and bromazepam in benzodiazepine dependence. Br. J. Psychiatry 1991, 158, 511–516, doi:10.1192/bjp.158.4.511.
[119]
Lemoine, P.; Ohayon, M.M. Is hypnotic withdrawal facilitated by the transitory use of a substitute drug? Prog. NeuroPsychopharmacol. Biol. Psychiatry 1997, 21, 111–124, doi:10.1016/S0278-5846(96)00162-5.
[120]
Cantopher, T.; Olivieri, S.; Cleave, N.; Edwards, J.G. Chronic benzodiazepine dependence. A comparative study of abrupt withdrawal under propranolol cover versus gradual withdrawal. Br. J. Psychiatry 1990, 156, 406–411, doi:10.1192/bjp.156.3.406.
[121]
Schweizer, E.; Rickels, K.; Case, W.G.; Greenblatt, D.J. Carbamazepine treatment in patients discontinuing long-term benzodiazepine therapy. Effects on withdrawal severity and outcome. Arch. Gen. Psychiatry 1991, 48, 448–452, doi:10.1001/archpsyc.1991.01810290060012.
